文献速递生殖医学

不孕症且抗苗勒管激素水平≤0.3 ng/mL女性的活产结局

Live-Birth Outcomes Among Women With Infertility and Anti-Müllerian Hormone Levels of 0.3 ng/mL or Lower.
PubMed 文献 · Obstet Gynecol · 2022-10-05

单中心回顾性队列纳入978例抗苗勒管激素(AMH)≤0.3 ng/mL的不孕症患者(2013-2019年),按SART年龄组分层。首个IVF周期活产率在各年龄组均显著低于2018年SART全国报告的单次启动周期活产率;35岁及以上者累计三个启动周期后活产率与全国单次周期相当。

要点

  • AMH≤0.3 ng/mL者首个IVF周期活产率在各年龄组均显著低于SART全国单次启动周期率
  • 35岁及以上患者累计三个启动周期活产率与SART全国单次周期活产率相当
  • 小于35岁者需纳入所有IVF及非IVF治疗周期后累计活产率才与全国单次IVF周期率相当

核心结论

  • 与全国结局相比,AMH≤0.3 ng/mL患者首个启动周期后的活产机会显著更低。
  • 35岁及以上患者累计三个启动周期后的活产率与全国单次启动周期活产结局相当。
  • 小于35岁患者仅当纳入所有IVF及非IVF治疗周期后,累计活产率才与全国单次IVF周期率相当。

研究设计与样本

  • 单学术中心回顾性队列研究,纳入2013-2019年启动一个或多个IVF周期的不孕症且AMH≤0.3 ng/mL患者。
  • 排除既往化疗、AMH检测前3个月内使用激素避孕及严重男性因素不孕者。
  • 按美国辅助生殖技术学会(SART)年龄组分层,共纳入978例患者,启动周期数中位数(四分位距)为2(1-3)。
  • 主要结局为每IVF周期活产率,与2018年SART全国汇总报告的单次意向取卵活产率比较,报告比例差(PD)及95%CI。

主要发现

  • 首个启动周期活产率:小于35岁26.2% vs SART 55.6%(PD 29.4%,95%CI 20.9-37.9%)。
  • 35-37岁15.9% vs 40.8%(PD 24.9%,95%CI 19.0-30.9%);38-40岁12.6% vs 26.8%(PD 14.3%,95%CI 10.2-18.3%)。
  • 41-42岁4.7% vs 13.4%(PD 8.7%,95%CI 5.9-11.6%);大于42岁1.2% vs 4.1%(PD 2.9%,95%CI 1.5-4.3%)。
  • 35-37、38-40、41-42及大于42岁患者累计三个启动周期活产率与SART全国单次启动周期活产率相当。
  • 小于35岁患者累计三个启动周期活产率仍显著低于SART全国单次启动周期率(PD 16.8%,95%CI 7.3-26.2%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To estimate the live-birth rate per in vitro fertilization (IVF) cycle and after cumulative infertility treatment among patients with anti-müllerian hormone (AMH) levels of 0.3 ng/mL or lower. METHODS: We conducted a retrospective cohort study at a single academic center of patients with infertility and AMH levels of 0.3 ng/mL or lower who initiated one or more IVF cycles (2013-2019). Exclusion criteria included prior chemotherapy, hormonal contraceptive use within 3 months of AMH level measurement, and severe male factor infertility. Patients were stratified by Society for Assisted Reproductive Technology (SART) age group. The primary outcome was live-birth rate per IVF cycle. Live-birth outcomes were compared with the 2018 SART National Summary Report for live births per single intended oocyte retrieval, with proportion difference (PD) and 95% CI reported. RESULTS: A total of 978 patients were included. The median (interquartile range) number of cycles initiated was 2 (1-3). With the first initiated cycle, the live-birth rate for those with AMH levels of 0.3 ng/mL or lower was significantly lower in each age category compared with the SART live-birth rate per single initiated cycle (younger than 35 years: 26.2% vs 55.6%, PD 29.4%, 95% CI 20.9-37.9%; 35-37 years: 15.9% vs 40.8%, PD 24.9%, 95% CI 19.0-30.9%; 38-40 years: 12.6% vs 26.8%, PD 14.3%, 95% CI 10.2-18.3%; 41-42 years: 4.7% vs 13.4%, PD 8.7%, 95% CI 5.9-11.6%; older than 42 years: 1.2% vs 4.1%, PD 2.9%, 95% CI 1.5-4.3%). In patients aged 35-37, 38-40, 41-42, and older than 42 years, the cumulative live-birth rate after up to three initiated cycles was comparable with the SART live-birth rate per single initiated cycle but remained significantly lower in patients younger than age 35 years (PD 16.8%, 95% CI 7.3-26.2%). After all treatments were included (cumulative IVF, ovulation induction, and unassisted cycles), live-birth rates were similar to SART live-birth rates per single initiated cycle in all age groups. CONCLUSION: Compared with national outcomes, patients with AMH levels of 0.3 ng/mL or lower had a significantly lower chance of live birth after their first initiated cycle. However, the cumulative live-birth rate after up to three initiated cycles was comparable with national live-birth outcomes per single initiated cycle in patients aged 35 years or older. In patients younger than age 35 years, only when all IVF and non-IVF treatment cycles were included did the cumulative live-birth rate become comparable with the national rate per single IVF cycle.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Romanski PA, Gelvin B, Bortoletto P, et al. Live-Birth Outcomes Among Women With Infertility and Anti-Müllerian Hormone Levels of 0.3 ng/mL or Lower. Obstet Gynecol. 2022. PMID: 36201783. doi:10.1097/AOG.0000000000004895

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。